Anti-Biofilm Wound Dressing Market Size Worth $1,154.2 Million By 2027 | CAGR: 9.2%

Anti-Biofilm Wound Dressing Market Size Worth $1,154.2 Million By 2027 | CAGR: 9.2%

The global anti-biofilm wound dressing market size is expected to reach USD 1,154.2 million by 2027 according to a new study by Polaris Market Research. The report “Anti-biofilm Wound Dressing Market Share, Size, Trends, Industry Analysis Report By Mode of Mechanism  (Physical (Ultrasound Debridement, Manual Debridement, Pulse Electrical Field), Biological (Bacteriophage, Lactoferrin, Dispersin B, Others), Chemical (EDTA, Ionic Silver, Iodine, Others)); By Application [Chronic Wounds (Venous Leg Ulcers, Pressure Ulcers, Diabetic Foot Ulcers, & Others)]; [Acute Wounds (Burn Wounds, Traumatic & Surgical Wounds)]; By End Use (Hospital, Wound Care Centers, Clinics & Others); By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.


Anti-biofilm is obtained from natural plants. The inhibition of biofilm formation includes the mechanism of the suppression of microbial adhesion & by the inhibition of polymer matrix & ECM generation with the interference at the bacterial co-aggregation & QS network. This antibiofilm dressing are utilised in the treatment of chronic wounds patients in the U.S. The Biofilm comprises of Microlyte which is ultra-thin in nature. Additionally, the dressing is composed of bioresorbable synthetic polymers. The biofilm includes ionic & metallic silver that destroy bacteria in dressing process on a wound surface.


Recent developments in anti-biofilm wound dressing include the usage of lactoferrin and xylitol antibiofilm development. Both lactoferrin and xylitol are naturally derived antimicrobials. They are more efficacious against existing biofilm. As lactoferrin and xylitol has been used to combat bacteria, the usage of these agents in combination therapy provides a variety of advantages as it is cost-effective, more easily available, biofilm-targeted therapy for both the wounds i.e. acute & chronic wounds.


Have Questions? Request a sample or make an Inquiry before buying this report by clicking the following link:


The prominent factors favoring the market growth include increasing chronic diseases and innovations in anti-biofilm wound procedures. As per the National Diabetes Statistic Report, 2017 around 100 million people within the U.S. are suffering from diabetes or prediabetes. Moreover, according to the International Diabetes Federation, the incidence of diabetes is predicted to rise from 366.0 million in 2011 to 552.0 million by 2030 worldwide. While prolonged diabetes is the reason for diabetic foot ulcers, the increasing cases of diabetes are predicted to positively influence the expansion of the global market.


The majority of the chronic wounds needs a prolonged recovery span, responsible for the frequent replacements of dressings. Hence, the demand for anti-biofilm wound dressing therapy are rising.  Meanwhile, the cases of sports injury are also rising as more & more people are now well acquainted with the benefits of the sports, due to which injury cases are also rising in larger extent which is boosting the market growth.


Market participants such as Urgo Medical, ConvaTec, Coloplast, Smith & Nephew PLC, Next Science, 3M, Monarch Labs, Mega Pharma (Pvt) Ltd., BioMonde, B. Braun Melsungen AG, Molnlycke Healthcare, Lohmann & Rauscher & Arobella Medical are some of the key players operating in the global market. Players in the market are focusing on the mergers & acquisitions, collaborations, product extension & geographical expansion. Additionally, the companies are making huge investments in research and development activities to develop new products & to compete with the other players.


Polaris Market Research has segmented the anti-biofilm wound dressing market report based on mode of mechanism, end use, application, and region


Anti-Biofilm Wound Dressing Mode of Mechanism Outlook (Revenue - USD Million, 2016 – 2027)

  • Physical
    • Ultrasound Debridement
    • Manual Debridement
    • Pulse Electrical Field
  • Biological
    • Bacteriophage
    • Lactoferrin
    • Dispersin B
    • Others
  • Chemical
    • EDTA
    • Ionic Silver
    • Iodine
    • Others

Anti-Biofilm Wound Dressing Application Outlook (Revenue - USD Million, 2016 – 2027)

  • Chronic Wounds
    • Venous Leg Ulcers
    • Pressure Ulcers
    • Diabetic Foot Ulcers
    • Others
  • Acute Wounds
    • Burn Wounds
    • Traumatic
    • Surgical Wounds

Anti-Biofilm Wound Dressing End User Outlook (Revenue - USD Million, 2016 – 2027)

  • Hospital
  • Wound Care Centers
  • Clinics
  • Others

Anti-Biofilm Wound Dressing Regional Outlook (Revenue - USD Million, 2016 – 2027)

  • North America
    • U.S.
    • Canada
  • Europe
    • France
    • Germany
    • UK
    • Italy
    • Spain
    • Netherlands
    • Austria
  • Asia Pacific
    • China
    • India
    • Japan
    • Malaysia
    • South Korea
    • Indonesia
  • Central & South America
    • Mexico
    • Brazil
    • Argentina
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa